New MS injection tested Head-to-Head against standard therapies

NCT ID NCT04788615

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study compared a monthly self-injected medication called ofatumumab against standard first-line MS therapies in people newly diagnosed with relapsing multiple sclerosis. The goal was to see which treatment was better at keeping the disease quiet—preventing relapses, stopping new brain lesions on MRI scans, and delaying disability progression. About 185 adults participated in this 15-month trial, which also monitored safety.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Bayonne, Bayonne Cedex, 64109, France
Novartis Investigative Site

Amiens, 80054, France
Novartis Investigative Site

Bordeaux, 33076, France
Novartis Investigative Site

Clermont-Ferrand, 63003, France
Novartis Investigative Site

Créteil, 94010, France
Novartis Investigative Site

Gonesse, 95500, France
Novartis Investigative Site

Grenoble, 38043, France
Novartis Investigative Site

Montpellier, 34090, France
Novartis Investigative Site

Nice, 06202, France
Novartis Investigative Site

Nîmes, 30029, France
Novartis Investigative Site

Poissy, 78303, France
Novartis Investigative Site

Rennes, 35033, France
Novartis Investigative Site

Strasbourg, 67000, France
Novartis Investigative Site

Frankfurt am Main, Hesse, 60590, Germany
Novartis Investigative Site

Westerstede, Lower Saxony, 26655, Germany
Novartis Investigative Site

Cologne, North Rhine-Westphalia, 50937, Germany
Novartis Investigative Site

Bayreuth, 95445, Germany
Novartis Investigative Site

Berlin, 12101, Germany
Novartis Investigative Site

Berlin, 13353, Germany
Novartis Investigative Site

Bielefeld, 33647, Germany
Novartis Investigative Site

Dortmund, 44137, Germany
Novartis Investigative Site

Heidelberg, 69120, Germany
Novartis Investigative Site

Siegen, 57076, Germany
Novartis Investigative Site

Ulm, 89073, Germany
Novartis Investigative Site

Montichiari, BS, 25018, Italy
Novartis Investigative Site

Milan, MI, 20132, Italy
Novartis Investigative Site

Roma, RM, 00133, Italy
Novartis Investigative Site

Roma, RM, 00189, Italy
Novartis Investigative Site

Orbassano, TO, 10043, Italy
Novartis Investigative Site

Napoli, 80131, Italy
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

Salt, Girona, 17190, Spain
Novartis Investigative Site

El Palmar, Murcia, 30120, Spain
Novartis Investigative Site

Barakaldo, Vizcaya, 48903, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Madrid, 28009, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Madrid, 28040, Spain
Novartis Investigative Site

Málaga, 29010, Spain
Novartis Investigative Site

Seville, 41009, Spain
Novartis Investigative Site

Valencia, 46026, Spain

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS